PL363239A1 - Silensed anti-cd28 antibodies and use thereof - Google Patents

Silensed anti-cd28 antibodies and use thereof

Info

Publication number
PL363239A1
PL363239A1 PL01363239A PL36323901A PL363239A1 PL 363239 A1 PL363239 A1 PL 363239A1 PL 01363239 A PL01363239 A PL 01363239A PL 36323901 A PL36323901 A PL 36323901A PL 363239 A1 PL363239 A1 PL 363239A1
Authority
PL
Poland
Prior art keywords
silensed
antibodies
silensed anti
Prior art date
Application number
PL01363239A
Other languages
English (en)
Polish (pl)
Inventor
Yun J. Tso
Paul Hinton
Maximiliano Vasouez
Kouichi Tamura
Yasuyuki Higasji
Nobuo Seki
Hirotsugu Ueda
Original Assignee
Fuijsawa Pharmaceutical Co, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fuijsawa Pharmaceutical Co, Ltd. filed Critical Fuijsawa Pharmaceutical Co, Ltd.
Publication of PL363239A1 publication Critical patent/PL363239A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
PL01363239A 2000-12-14 2001-12-14 Silensed anti-cd28 antibodies and use thereof PL363239A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25515500P 2000-12-14 2000-12-14

Publications (1)

Publication Number Publication Date
PL363239A1 true PL363239A1 (en) 2004-11-15

Family

ID=22967074

Family Applications (1)

Application Number Title Priority Date Filing Date
PL01363239A PL363239A1 (en) 2000-12-14 2001-12-14 Silensed anti-cd28 antibodies and use thereof

Country Status (18)

Country Link
EP (1) EP1341553A4 (ko)
JP (1) JP2004515243A (ko)
KR (1) KR20040020866A (ko)
CN (1) CN1272345C (ko)
AR (1) AR031924A1 (ko)
AU (2) AU2002226086C1 (ko)
BR (1) BR0116686A (ko)
CA (1) CA2432736A1 (ko)
CZ (1) CZ20031909A3 (ko)
HU (1) HUP0400697A3 (ko)
IL (1) IL156262A0 (ko)
MX (1) MXPA03005327A (ko)
NO (1) NO20032542L (ko)
NZ (1) NZ526569A (ko)
PL (1) PL363239A1 (ko)
RU (1) RU2261723C2 (ko)
WO (1) WO2002047721A1 (ko)
ZA (1) ZA200305384B (ko)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080095774A1 (en) * 2001-02-16 2008-04-24 Wyeth Agents and Methods for Specifically Blocking CD28-Mediated Signaling
US7531168B2 (en) 2001-02-16 2009-05-12 Genetics Institute Llc Method for downmodulating immune response in type I diabetes
EP1909831A4 (en) 2005-06-14 2013-02-20 Amgen Inc PREPARATIONS OF SPONTANEOUS TAMPING PROTEINS
FR2951176A1 (fr) 2009-10-09 2011-04-15 Tcl Pharma Ligands monovalents du recepteur cd28 humain
CA2788544C (en) * 2010-02-18 2019-03-05 Effimune Anti-cd28 humanized antibodies
BR112019007858A2 (pt) 2016-10-21 2019-07-02 Amgen Inc formulações farmacêuticas e métodos para produzir as mesmas
CA3103629A1 (en) 2018-06-15 2019-12-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
WO2020183471A1 (en) * 2019-03-14 2020-09-17 Biond Biologics Ltd. A method for immunosuppression
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
JP2023509359A (ja) 2019-12-17 2023-03-08 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド 鉄依存性細胞分解の誘導物質との併用抗癌療法
CN116096906A (zh) 2020-06-29 2023-05-09 旗舰创业创新五公司 工程化以促进萨诺传递的病毒及其在治疗癌症中的用途
KR102607909B1 (ko) 2020-08-19 2023-12-01 젠코어 인코포레이티드 항-cd28 조성물
CA3214085A1 (en) 2021-03-31 2022-10-06 Darby Rye Schmidt Thanotransmission polypeptides and their use in treating cancer
KR20240026507A (ko) 2021-06-29 2024-02-28 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 타노트랜스미션을 촉진시키도록 엔지니어링된 면역 세포 및 이의 용도
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580756A (en) * 1990-03-26 1996-12-03 Bristol-Myers Squibb Co. B7Ig fusion protein

Also Published As

Publication number Publication date
CN1272345C (zh) 2006-08-30
AU2608602A (en) 2002-06-24
AU2002226086C1 (en) 2006-03-09
BR0116686A (pt) 2003-12-30
RU2261723C2 (ru) 2005-10-10
EP1341553A1 (en) 2003-09-10
IL156262A0 (en) 2004-01-04
AU2002226086B2 (en) 2005-08-25
EP1341553A4 (en) 2004-07-28
RU2003121231A (ru) 2005-02-10
AR031924A1 (es) 2003-10-08
ZA200305384B (en) 2004-10-11
WO2002047721A1 (en) 2002-06-20
HUP0400697A2 (hu) 2004-06-28
MXPA03005327A (es) 2004-12-03
NO20032542L (no) 2003-08-07
KR20040020866A (ko) 2004-03-09
JP2004515243A (ja) 2004-05-27
CZ20031909A3 (cs) 2003-11-12
CA2432736A1 (en) 2002-06-20
HUP0400697A3 (en) 2007-05-02
CN1489473A (zh) 2004-04-14
NO20032542D0 (no) 2003-06-05
NZ526569A (en) 2005-07-29

Similar Documents

Publication Publication Date Title
HK1208705A1 (en) Multivalent antibodies and uses therefor
TWI316088B (en) Anti-tnf alpha antibodies and their uses
GB0029360D0 (en) Humanised antibodies and uses thereof
IL225633A0 (en) Antibodies against alpha v beta 6 and uses thereof
EP1551447A4 (en) ANTI-ADDL ANTIBODIES AND USES THEREOF
IL154325A (en) Isolated anti-il-12 antibody and composition comprising the same
HUP0302128A3 (en) Anti-dual integrin antibodies, compositions, methods and uses
GB9927332D0 (en) Novel antibody and uses thereof
IL156161A0 (en) Substituted 2-anilino-benzimidazoles and the use thereof as nhe-inhibitors
HUP0400697A3 (en) Silensed anti-cd28 antibodies and use thereof
AU2003219093A8 (en) Anti-hpv-16 e7 antibodies and their use
EP1589033A4 (en) ANTIBODY AND ITS USE
IL166063A0 (en) Antibodies and uses thereof
GB0026134D0 (en) Peptides and their use
EP1302770A4 (en) PARTICLE MARKING PROTEIN AND IMMUNO-CHROMATOGRAPHER USING THE SAME
GB0007530D0 (en) Trityl-type compounds and their use
GB0021497D0 (en) Compounds and their use
EP1627888A4 (en) ANTIBODY AND ITS USE
EP1437367A4 (en) ANTIBODIES AND ITS USE
GB0003527D0 (en) Antibodies
GB0005071D0 (en) Antibodies
GB0227080D0 (en) Antibodies and uses thereof
GB0002559D0 (en) Virulencegene and protein and their use
GB0017139D0 (en) Human monoclonal antibodies
GB0016824D0 (en) Human monoclonal antibodies

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)